国家药监局：开展药品经营环节“清源”巩固提升行动

Core Viewpoint - The national drug supervision management meeting held in Beijing from January 6 to 7 aims to summarize the drug regulation work of 2025 and outline key tasks for 2026, emphasizing the importance of drug safety and the support for the high-quality development of the pharmaceutical industry [1][3][4]. Group 1: Drug Regulation Achievements and Goals - The drug supervision system has implemented the "four strictest" requirements, leading to a historical high in the approval of innovative drugs and medical devices, while maintaining overall drug safety stability [3][4]. - The meeting highlighted the completion of major development goals and tasks outlined in the "14th Five-Year Plan" for drug safety and high-quality development, marking a new starting point for drug regulation reform [3][4]. Group 2: Key Tasks for 2026 - The focus for 2026 includes ensuring high-level drug safety, enhancing clinical trial supervision, and increasing inspection efforts on high-risk products [5]. - Support for the pharmaceutical industry will be strengthened through comprehensive regulatory reforms, promoting innovation in drug development, and enhancing the self-reliance of medical devices [5]. - The legal framework for drug regulation will be improved, with an emphasis on increasing the authority and credibility of administrative enforcement [5]. Group 3: Leadership and Governance - The meeting stressed the importance of strengthening the Party's leadership in drug regulation and integrating high-quality Party building with regulatory work [6]. - Drug regulatory departments are urged to enhance supervision during the upcoming holiday season to ensure public safety and combat illegal drug-related activities [6].